Moreover, we have previously shown a significant reduction of mutant ATXN3 aggregation and neurological dysfunction in a C. elegans model of MJD upon VPA treatment through the protective role of the transcription factor DAF-16, supporting a role in protection against proteotoxicity related to aging and cell survival [21]. The gene discussed is ATXN3; the disease is Machado-Joseph disease.